NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by ...

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction ...

Each year, scientists present countless research posters at conferences, symposia and academic gatherings, making the poster one of the most common—and most visible—forms of scientific communication.

For the selected target, LabGenius has developed a selectivity-enhanced TCE. The company’s lead optimisation platform, EVA™,was used to discover and concomitantly optimise a TCE with improved killing ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced ...

Cyclin D1 is overexpressed in certain solid tumors and hematologic malignancies. In these cancers, the cyclin D1/CDK4 complex drives cell proliferation by binding to the tumor suppressor ...

Session A-2 Room 339: Leverage AI in Psychology: Finding a Use Case Presentation 1: Finding a Use Case: Building a Scheduling GPT: Olivia Velez, Psychology Presentation 2: Finding a Use Case: Natural ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

Zentalis Pharmaceuticals, Inc. announced that an abstract has been accepted for a poster presentation at the 2025 American Society of Clinical Oncology Annual Meeting, scheduled for May 30 to June 3 ...

Presenting your poster at a Labroots Virtual Event can provide valuable research insights and feedback from peers in the comfort of your home or office. Every Labroots virtual event features a virtual ...

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics (AKBA) ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...